Your browser is no longer supported. Please, upgrade your browser.
CRSP CRISPR Therapeutics AG daily Stock Chart
CRISPR Therapeutics AG
Index- P/E- EPS (ttm)-0.46 Insider Own0.40% Shs Outstand60.69M Perf Week-9.69%
Market Cap3.97B Forward P/E- EPS next Y-4.82 Insider Trans-47.11% Shs Float38.60M Perf Month18.84%
Income-11.30M PEG- EPS next Q-0.63 Inst Own46.80% Short Float9.37% Perf Quarter31.59%
Sales212.70M P/S18.65 EPS this Y-101.60% Inst Trans0.58% Short Ratio3.81 Perf Half Y38.86%
Book/sh10.79 P/B6.06 EPS next Y-1828.00% ROA-2.00% Target Price77.50 Perf Year95.45%
Cash/sh10.38 P/C6.30 EPS next 5Y- ROE-2.60% 52W Range22.22 - 74.00 Perf YTD128.77%
Dividend- P/FCF217.95 EPS past 5Y- ROI-40.70% 52W High-11.68% Beta-
Dividend %- Quick Ratio8.30 Sales past 5Y- Gross Margin- 52W Low194.15% ATR4.07
Employees188 Current Ratio8.30 Sales Q/Q37542.60% Oper. Margin-4.50% RSI (14)55.82 Volatility5.26% 6.81%
OptionableYes Debt/Eq0.00 EPS Q/Q324.60% Profit Margin-5.30% Rel Volume0.78 Prev Close66.03
ShortableYes LT Debt/Eq0.00 EarningsJan 27 BMO Payout- Avg Volume950.05K Price65.36
Recom2.10 SMA20-1.40% SMA5024.27% SMA20044.06% Volume737,081 Change-1.01%
Nov-19-19Upgrade William Blair Mkt Perform → Outperform
Nov-12-19Upgrade Oppenheimer Perform → Outperform $65
Aug-01-19Initiated Jefferies Buy $64
Jul-26-19Initiated Canaccord Genuity Buy $72
Jun-10-19Initiated ROTH Capital Buy $50
Apr-12-19Initiated Evercore ISI Outperform
Mar-14-19Initiated William Blair Mkt Perform
Jan-28-19Downgrade Goldman Buy → Neutral
Jan-22-19Downgrade Citigroup Neutral → Sell
Nov-30-18Initiated Needham Buy $62
Oct-10-18Initiated Wells Fargo Outperform $65
Oct-10-18Initiated Guggenheim Neutral
Sep-21-18Initiated Raymond James Underperform
May-15-18Reiterated Chardan Capital Markets Buy $25 → $72.50
Apr-06-18Initiated Goldman Buy $86
Mar-08-18Initiated JMP Securities Mkt Outperform $69
Jan-23-18Upgrade SunTrust Hold → Buy
Dec-22-17Initiated Piper Jaffray Overweight
Jul-14-17Initiated SunTrust Hold $16
Mar-28-17Initiated Chardan Capital Markets Buy $23.50
Dec-11-19 03:41PM  What the Tech? Zacks
01:59PM  Did Hedge Funds Drop The Ball On CRISPR Therapeutics AG (CRSP) ? Insider Monkey
Dec-10-19 03:08PM  Find Strong Stocks Heading into 2020 with this First Profit Screen Zacks
Dec-04-19 05:31PM  Trade of the 2020's: Sell Gold, Buy Biotech Zacks
Dec-03-19 01:03AM  Don't Judge a Month by its First Day Zacks +6.57%
Nov-29-19 12:15PM  Biotech Tops in November: Best ETFs & Stocks Zacks +5.20%
11:30AM  The Zacks Analyst Blog Highlights: GLD, CRSP, GBT, ALNY and ARKG Zacks
Nov-27-19 05:33PM  Why Gold is Headed to Zero -- And What You Should Buy Instead Zacks
07:00AM  CRISPR Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire
Nov-26-19 07:06PM  Why Biotech ETFs Surged in Monday's Trading Session Zacks
Nov-25-19 06:55PM  Genomics ETFs Surge on CRISPR's Gene Editing Progress Zacks +5.58%
Nov-22-19 03:12PM  Crispr Therapeutics Stock Surged; Was It A Sell? Investor's Business Daily
02:11PM  Consider Adding New Positions in U.S. Cannabis Stocks InvestorPlace
Nov-21-19 10:24AM  Vertex (VRTX) Gets French Reimbursement for CF Drug Orkambi Zacks -11.91%
07:22AM  The Daily Biotech Pulse: Patent Win For Cellectis, Hepion Proves Efficacy In Animal Model, Job Cuts At Neon Benzinga
Nov-20-19 09:18PM  CRISPR Therapeutics Announces Pricing of Public Offering of Common Shares GlobeNewswire
10:45AM  Crispr Therapeutics Rises After Company Announces Stock Sale
10:19AM  Company News For Nov 20, 2019 Zacks
09:31AM  Biotech Stock Roundup: MYOV & KRTX Surge, Pipeline Updates From VRTX, CELG & More Zacks
09:12AM  Vertex, CRISPR's Gene Editing Drug Shows Positive Early Data Zacks
07:25AM  The Daily Biotech Pulse: Endo's Cellulite Treatment Accepted For Review, Diffusion Pharma Reports Positive Glioblastoma Data Benzinga
01:05AM  The NASDAQ Needs No Break Zacks
Nov-19-19 05:20PM  Biotech Stock Pops On Promising First In-Human CRISPR Gene-Editing Drug Investor's Business Daily +16.97%
04:28PM  Biotech Stock Pops On Promising First In-Human CRISPR Gene-Editing Drug Investor's Business Daily
04:14PM  CRISPR Therapeutics Announces Proposed Public Offering of Common Shares GlobeNewswire
03:37PM  [video]Shares of CRISPR Therapeutics Fall in After Hours Trading on Share Offering
11:40AM  Crispr's Gene-Editing Therapy Found Effective In Treating Blood Disorders In Early-Stage Study Benzinga
11:25AM  Crispr Therapeutics Stock Spikes on Positive Gene-Editing Results
10:46AM  CRISPR Therapeutics stock jumps on early gene editing data American City Business Journals
07:56AM  The Daily Biotech Pulse: Therapix To Reverse Merge With CBD Company, Crispr Gene Editing Therapy Readout Benzinga
07:00AM  CRISPR Therapeutics and Vertex Announce Positive Safety and Efficacy Data From First Two Patients Treated With Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001® for Severe Hemoglobinopathies GlobeNewswire
Nov-14-19 01:27PM  AMD, Amarin and Crispr are three stocks to watch for potentially higher prices MarketWatch
Nov-13-19 10:00AM  Editas (EDIT) Beats on Q3 Earnings, Amends Celgene Deal Zacks
Nov-08-19 02:20PM  FDA approves Acceleron's blood disorder drug ahead of schedule American City Business Journals
Nov-04-19 05:05PM  15 Stocks With A High Current Ratio Benzinga
Oct-31-19 12:33PM  Vertex (VRTX) Q3 Earnings Beat, Revenues Lag Estimates Zacks
04:30AM  8 Undervalued Biotech Stocks to Watch Now Investopedia
Oct-29-19 04:05PM  Experts Talk Hot Biotech Stocks at Barrons Breakfast +9.07%
03:16PM  Investors Can Find Strong Stocks with our First Profit Screen Zacks
01:30PM  Boston firms return to Saudi conference after journalists murder American City Business Journals
Oct-28-19 02:58PM  BTIG: Crispr Could Be A Takeover Target For Vertex Benzinga +12.55%
08:15AM  CRISPR Therapeutics AG (CRSP) Q3 Earnings and Revenues Surpass Estimates Zacks
07:00AM  CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2019 Financial Results GlobeNewswire
Oct-25-19 12:06PM  Can CF Drugs Drive Growth for Vertex (VRTX) in Q3 Earnings? Zacks
Oct-23-19 04:24PM  Navigating The Healthcare Industry: Science Fiction Turns to Reality Zacks
02:15PM  Is CRISPR Therapeutics AG (CRSP) Going To Burn These Hedge Funds ? Insider Monkey
Oct-16-19 10:13AM  CRISPR Therapeutics Enters New License Agreement, Shares Up Zacks
09:15AM  Earnings Season Makes Good First Impression Zacks
Oct-15-19 07:00AM  CRISPR Therapeutics and KSQ Therapeutics Announce License Agreement to Advance Companies Respective Cell Therapy Programs in Oncology GlobeNewswire
Oct-02-19 09:29AM  Vertex Enters Into Collaboration With Privately-Held Ribometrix Zacks
Oct-01-19 07:00AM  CRISPR Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire -6.00%
Sep-30-19 06:21AM  CRISPR gene editing startup Beam Therapeutics plans $100M IPO American City Business Journals
Sep-21-19 08:37AM  CRISPR Therapeutics (NASDAQ:CRSP) Is In A Strong Position To Grow Its Business Simply Wall St.
Sep-17-19 07:00AM  CRISPR Therapeutics and ViaCyte Present Positive In Vitro Data Towards a Potential Immune-Evasive Cell Replacement Therapy for Diabetes at EASD 2019 GlobeNewswire
Sep-05-19 03:07PM  Probability 101: How Not to Be a Sucker Zacks
Aug-27-19 09:10AM  CRISPR gene-editing technique set to push new boundaries MarketWatch
Aug-26-19 11:34PM  Gene editing: even Crispr Financial Times
Aug-07-19 09:32AM  Editas (EDIT) Misses on Q2 Earnings & Sales, Gets New CEO Zacks
Aug-06-19 10:04AM  Vertex Has "Significant Financial Firepower" Motley Fool +5.56%
Aug-01-19 12:00PM  Vertex (VRTX) Beats on Q2 Earnings, Ups CF Product Sales View Zacks
06:16AM  Legal fight over Broad Institute's patent for CRISPR gene editing flares up again American City Business Journals
Jul-31-19 12:41PM  Is Intellia Therapeutics a Buy? Motley Fool
07:01AM  CRISPR Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire
Jul-29-19 05:45PM  CRISPR Therapeutics AG (CRSP) Reports Q2 Loss, Lags Revenue Estimates Zacks
04:01PM  CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2019 Financial Results GlobeNewswire
11:40AM  Axovant (AXGT) to Post Q1 Earnings: What's in the Cards? Zacks
Jul-26-19 11:49AM  Vertex (VRTX) to Post Q2 Earnings: What's in the Cards? Zacks
Jul-25-19 11:20AM  Where Will CRISPR Therapeutics Be in 5 Years? Motley Fool
Jul-24-19 10:25AM  Jim Cramer Gives His Opinion On eBay, Pfizer And More Benzinga
Jul-23-19 05:03PM  Is Vertex Pharmaceuticals a Buy? Motley Fool
04:44PM  CRISPR Could Change Medicine, But Not in the Way Wall Street Expects Motley Fool
Jul-18-19 09:00AM  2 Supercharged Growth Stocks I'd Buy Right Now Motley Fool
Jul-17-19 03:40PM  Can We Find The Right Stock Using Our Newly Found Insight? Zacks
Jul-16-19 06:05PM  Should You Pick Up Novartis (NVS) Before Q2 Earnings? Zacks
10:07AM  Novartis' (NVS) Crizanlizumab Gets Priority Review From FDA Zacks
Jul-11-19 04:26PM  Getting technical: Buyers in control of Crispr Therapeutics (CRSP) Yahoo Finance Video
Jul-10-19 08:16AM  Here's Why CRISPR Gene Editing Stocks Rose as Much as 32.4% in June Motley Fool
Jul-01-19 04:01PM  CRISPR Therapeutics Announces Oral Presentation at the 55th Annual Meeting of the European Association for the Study of Diabetes GlobeNewswire
Jun-29-19 04:35PM  3 Growth Stocks to Buy and Hold for the Next 50 Years Motley Fool
Jun-28-19 09:42PM  Did Hedge Funds Drop The Ball On CRISPR Therapeutics AG (CRSP) ? Insider Monkey
Jun-23-19 10:48AM  What Kind Of Shareholders Own CRISPR Therapeutics AG (NASDAQ:CRSP)? Simply Wall St.
10:45AM  How Many CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Do Institutions Own? Simply Wall St.
Jun-18-19 09:15AM  Fed Week Begins in the Green Zacks
Jun-13-19 01:43PM  J.P. Morgan Chase Commercial Mortgage Securities Trust 2019-OSB -- Moody's assigns definitive ratings to six CMBS classes of J.P. Morgan Chase Commercial Mortgage Securities Trust 2019-OSB Moody's
10:47AM  Undeterred by Vertex's plans, biotech Dyne enters Duchenne drug fray American City Business Journals
Jun-12-19 09:27AM  Biotech Stock Roundup: Celgene Submits MS Drug to FDA, INSY & CBAY Crash Zacks
Jun-11-19 06:00AM  Is the Newest Gene Editing Stock a Buy? Motley Fool
Jun-10-19 09:29AM  CRISPR Therapeutics Up on Collaboration Expansion by Vertex Zacks
Jun-09-19 07:27AM  Gene Therapy vs. Gene Editing: Which Is Better for Tackling Muscular Dystrophy? Motley Fool
Jun-07-19 09:54AM  Vertex Signs Gene Editing Deals With Crispr, Exonics Worth Up To $2 Billion Benzinga +15.11%
09:54AM  Vertex Pharmaceuticals Bets on Gene Therapy With New Acquisition
09:24AM  Vertex Expands Collaboration With CRISPR, Acquires Exonics Zacks
07:24AM  The Daily Biotech Pulse: Vertex Bets Big On Gene-Editing Therapies, Sanofi Poaches Novartis For CEO Role, Relief In Europe for Endologix Benzinga
Jun-06-19 06:10PM  Vertex enters Duchenne field with $245M buy of Exonics American City Business Journals
05:12PM  Vertex Expands into New Disease Areas and Enhances Gene Editing Capabilities Through Expanded Collaboration with CRISPR Therapeutics and Acquisition of Exonics Therapeutics Business Wire
May-31-19 08:25AM  Vertex Selects Triple Combo Regimen for Regulatory Submission Zacks
May-30-19 02:36PM  3 Top Gene Therapy Stocks That Could Soar InvestorPlace
May-29-19 07:55PM  J.P. Morgan Chase Commercial Mortgage Securities Trust 2019-OSB -- Moody's assigns a provisional rating to One CMBS class of J.P. Morgan Chase Commercial Mortgage Securities Trust 2019-OSB Moody's
07:00AM  CRISPR Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire
May-28-19 03:56PM  J.P. Morgan Chase Commercial Mortgage Securities Trust 2019-OSB -- Moody's assigns provisional ratings to six CMBS classes of J.P. Morgan Chase Commercial Mortgage Securities Trust 2019-OSB Moody's
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious diseases. The company develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), a revolutionary gene editing technology that allows for precise directed changes to genomic DNA. It has a portfolio of therapeutic programs in a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. The company is also developing CTX110, a donor-derived gene-edited allogeneic CAR-T therapy targeting cluster of differentiation 19 positive malignancies. In addition, it is developing allogeneic CAR-T programs comprising CTX120 targeting B-cell maturation antigen for the treatment of multiple myeloma; and CTX130 for the treatment of solid tumors and hematologic malignancies. Further, the company engages in developing regenerative medicine programs in diabetes; and in vivo and other genetic disease programs to treat glycogen storage disease Ia, duchenne muscular dystrophy, cystic fibrosis, and hurler syndrome. It partners with biopharma companies, academic centers, universities, and other organizations. The company has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to develop and commercialize products for the treatment of Duchenne M. CRISPR Therapeutics AG is headquartered in Zug, Switzerland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
CAGNONI PABLO JDirectorNov 19Option Exercise5.597,50041,9257,500Nov 21 04:07 PM
Novak RodgerPresidentNov 19Option Exercise14.4333,618485,10833,618Nov 21 04:09 PM
Bolzon Bradley J PhDDirectorNov 19Sale67.4128,2551,904,783596,741Nov 21 07:53 PM
Bolzon Bradley J PhDDirectorNov 19Sale67.4113,745926,6050Nov 21 07:53 PM
Novak RodgerPresidentNov 19Sale70.0033,6182,353,2600Nov 21 04:09 PM
CAGNONI PABLO JDirectorNov 19Sale62.007,500465,0000Nov 21 04:07 PM
CAGNONI PABLO JDirectorNov 12Option Exercise5.597,50041,9257,500Nov 13 04:30 PM
CAGNONI PABLO JDirectorNov 12Sale55.007,500412,5000Nov 13 04:30 PM
CAGNONI PABLO JDirectorOct 30Option Exercise5.597,50041,9257,500Nov 01 06:35 PM
CAGNONI PABLO JDirectorOct 30Sale52.007,500390,0000Nov 01 06:35 PM
Bolzon Bradley J PhDDirectorOct 30Sale51.8921,0001,089,67513,745Nov 01 06:34 PM
Klein Lawrence OttoChief Business OfficerJul 11Option Exercise5.868,42149,34728,421Jul 12 04:13 PM
Klein Lawrence OttoChief Business OfficerJul 11Sale50.018,421421,17120,000Jul 12 04:13 PM
Klein Lawrence OttoChief Business OfficerJul 10Option Exercise5.8611,57967,85331,579Jul 12 04:13 PM
Klein Lawrence OttoChief Business OfficerJul 10Sale50.0211,579579,18220,000Jul 12 04:13 PM
Novak RodgerPresidentJul 10Sale50.0050,0002,500,065848,007Jul 12 04:10 PM
Kulkarni SamarthChief Executive OfficerJun 17Option Exercise1.8120,00036,200185,801Jun 19 04:15 PM
Kulkarni SamarthChief Executive OfficerJun 17Sale46.0020,000920,000165,801Jun 19 04:15 PM
Novak RodgerPresidentJun 10Sale45.0050,0002,250,000898,007Jun 12 04:16 PM
Kulkarni SamarthChief Executive OfficerApr 29Option Exercise1.8120,00036,200186,542May 01 04:05 PM
Kulkarni SamarthChief Executive OfficerApr 29Sale42.0320,000840,600166,542May 01 04:05 PM
Novak RodgerPresidentMar 04Sale40.4576,5273,095,240948,007Mar 05 05:59 PM
Novak RodgerPresidentMar 01Sale40.018,693347,7961,024,534Mar 05 05:59 PM
Novak RodgerPresidentFeb 25Sale40.0014,780591,2331,033,227Feb 27 04:10 PM
Novak RodgerPresidentJan 09Sale35.0182,6902,894,9771,048,007Jan 10 04:09 PM
Novak RodgerPresidentJan 08Sale35.0917,310607,4081,130,697Jan 10 04:09 PM
Vertex Pharmaceuticals (Europe10% OwnerDec 27Buy24.9527,461685,1165,380,940Dec 28 04:34 PM
Vertex Pharmaceuticals (Europe10% OwnerDec 26Buy24.8912,737317,0775,353,479Dec 28 04:34 PM
Vertex Pharmaceuticals (Europe10% OwnerDec 24Buy24.5868,0001,671,4825,340,742Dec 26 04:35 PM
Vertex Pharmaceuticals (Europe10% OwnerDec 21Buy22.5822,742513,4785,272,742Dec 26 04:35 PM
EMSTER KURT VONDirectorDec 18Sale29.7069,9252,077,1011,164,268Dec 19 04:22 PM
EMSTER KURT VONDirectorDec 17Sale33.173,00999,7971,234,193Dec 19 04:22 PM